Inactive Instrument

News Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

CAC40: in green, gains over 2% on a weekly basis	23-03-03	CF
CAC40: PMI and ISM data point to 22nd week of gains	23-03-03	CF
CAC40: 7350 in sight if rates continue to ease	23-03-03	CF
CAC40: breaks through 7300 pts after Bostic's comments	23-03-03	CF
Ipsen: acquisition of Albireo Pharma finalized	23-03-03	CF
French Drugmaker Ipsen Concludes Albireo Pharma Takeover	23-03-02	MT
ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-03-02	AQ
Albireo Pharma, Inc. Announces Board Changes	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index	23-03-02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index	23-03-02	CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.	23-02-28	CI
Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance	23-02-22	MT
Ipsen: extension of the deadline for its tender offer for Albireo Pharma	23-02-22	CF
Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome	23-02-15	AQ
Albireo Pharma's Bylvay Granted Priority Review for Rare Genetic Disorder Alagille Syndrome Treatment	23-02-14	MT
Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome	23-02-14	DJ
ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-02-14	AQ
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome	23-02-14	AQ
Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application	23-02-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Summary

Filters